Baseline patient characteristics by C-reactive protein levels.

Baseline patient characteristics by C-reactive protein levels.</p

Frequency distribution of high-sensitivity C-reactive protein (CRP) levels in heart failure with preserved ejection fraction.

Overall, median CRP levels were 3.69mg/L (interquartile range 1.83–8.12 mg/L with a range of 0.16 to 44.0 mg/L).</p

Exercise performance by baseline C-reactive protein levels (CRP).

Exercise performance by baseline C-reactive protein levels (CRP).</p

Baseline cardiac function by C-reactive protein levels.

Baseline cardiac function by C-reactive protein levels.</p

Comorbidity burden and C-reactive protein (CRP) levels.

CRP levels increased as the number of comorbidities increased (parameter estimate 0.70 per increment in comorbidity number, 95%CI 0.14–1.27, P = 0.02), even after adjustment for age and statin use (parameter estimate 0.92, 95% CI 0.35–1.49, P = 0.002). Data presented as n (percent) and median (interquartile range). Comorbidities include obesity (body mass index > 30), hypertension, ischemic heart disease, atrial fibrillation, diabetes mellitus, chronic obstructive pulmonary disease, anemia, and chronic kidney disease.</p

The relationship between C-reactive protein (CRP) and endothelin-1 and aldosterone in heart failure with preserved ejection fraction.

CRP was significantly associated with endothelin-1 and aldosterone. Ln indicates log transformed. *Adjusted for age, BMI and statin use.</p

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

 The above raphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite). </div